Boston Scientific buys women's health specialist nVision for $275 million
Companies said the FDA-cleared technology will increase earlier diagnoses of the fifth leading cause of cancer deaths among women.
Powered by WPeMatico
Companies said the FDA-cleared technology will increase earlier diagnoses of the fifth leading cause of cancer deaths among women.
Powered by WPeMatico